CRP and depressive symptom measurement: These observations have led to the concept of an “inflamed-depression” subtype, in which elevated C-reactive protein or interleukin-6 predicts poorer SSRI response yet may identify patients who benefit from alternative agents or anti-inflammatory augmentation [70, 71].